Don't Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD

Heading into the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, few planned data releases garnered as much attention and anticipation as the EMPACT-MI trial offered the prospect of further insight into the effects of SGLT2 inhibitors among a patient population with acute myocardial infarction.

An event-driven, double-blind, randomized, placebo-controlled trial, EMPACT-MI randomized 6522 patients in a 1:1 ratio to empagliflozin or placebo in addition to standard of care within 14 days of admission, with 3260 randomized to empagliflozin and 3262 randomized to placebo. The trial’s primary endpoint was a composite of first hospitalization for heart failure and all-cause mortality assessed in a time-to-first-event analysis.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.